Surrogate end points are bad for your health

If I told you that a drug went on sale on 1st September 2015, which involved fortnightly injections at a cost of £4,000 a year and for which trials on incidents or deaths had not even started, you might be shocked. That’s exactly what happened last week. A drug named “Repatha” went on sale, having been “granted marketing authorisation” (not approval?!) by the European Medicines agency on 21st May ...

 

The rest of this article is available to Club Members, who get access to all our articles, videos, recipes and newsletters.
To continue reading, please login or sign up for a membership. Thank you.

Sign up here for membership access...

Single Sign On provided by vBSSO